PPAR-γ agonists are widely used in the treatment of metabolic and inflammatory diseases, including type 2 diabetes, atherosclerosis, and non-alcoholic fatty liver disease (NAFLD) [58,59]. Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.